Pixium Vision

Overview
Price performance
Financials
Research
Sector insights
Thematics

Pixium Vision develops bionic vision systems for patients with severe vision loss. Its lead product, Prima, is a wireless sub-retinal implant system designed for Dry-ARMD. The company has completed a human feasibility study for Prima in Europe and expects to start implantations in a US feasibility study in H119.

Latest Insights

Healthcare |
Flash note

10.10.23

Pixium Vision — Safeguard proceedings underway

Healthcare |
Update

11.08.23

Pixium Vision — Shareholder loan extends runway

Healthcare |
Update

02.05.23

Pixium Vision — Focusing on reaching the PRIMAvera milestone

Healthcare |
Flash note

31.03.23

Pixium Vision — Breakthrough designation provides validation

Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(6.9)	(92.8)	(97.1)
Relative	(13.0)	(92.8)	(97.3)
52 week high/low	€0.2/€0.0

Financials

Edison Investment Research is terminating coverage on Kinarus Therapeutics (KNRS), Numis Corporation (NUM), EMIS Group (EMIS), Pixium Vision (PIX) and Treatt (TET). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via website

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2021A	2.7	(9.7)	(10.9)	(23.06)	N/A	N/A
2022A	2.0	(11.5)	(10.3)	(21.09)	N/A	N/A
2023E	N/A	N/A	N/A	N/A	N/A	N/A
2024E	N/A	N/A	N/A	N/A	N/A	N/A

Research

Flash note

Healthcare

04.08.22

Pixium Vision — Remote rehabilitation system approved

Update

Healthcare

27.07.22

Pixium Vision — ESGO financing deal shores up balance sheet

Healthcare

Flash note

14.09.22

Pixium Vision — First Prima implantation in Italy

Update

Healthcare

07.03.22

Pixium Vision — Moving ahead as expected

Update

Healthcare

15.12.21

Pixium Vision — PRIMAvera recruitment timing pushed out

Flash note

Healthcare

20.10.21

Pixium Vision — Three-year data confirms continued Prima safety

Outlook

Healthcare

05.10.21

Pixium Vision — Advancing towards sight restoration in dry-AMD

edison tv

Healthcare

27.08.21

Pixium Vision – executive interview

Update

Healthcare

16.07.21

Pixium Vision — Capital increase strengthens funding runway

Update

Healthcare

08.06.21

Pixium Vision — Signalling an intent to access US investors

Update

Healthcare

07.04.21

Pixium Vision — Back to basics as Second Sight deal is called off

Flash note

Healthcare

26.03.21

Pixium Vision — Second Sight $28m financing adds clouds to deal

Update

Healthcare

03.03.21

Pixium Vision — FY20 results in line, awaiting merger updates

edison tv

Healthcare

03.02.21

Pixium Vision – Edison Open House interview

Update

Healthcare

11.01.21

Pixium Vision — Pixium Vision to combine with Second Sight

Update

Healthcare

25.11.20

Pixium Vision — ANSM approval to start PRIMAvera pivotal study

Update

Healthcare

29.10.20

Pixium Vision — Q3 results in line, awaiting pivotal study approval

Flash note

Healthcare

28.07.20

Pixium Vision — H120 results broadly in line

Update

Healthcare

09.07.20

Pixium Vision — €7.3m capital increase completed

Outlook

Healthcare

22.06.20

Pixium Vision — Restoring eyesight in advanced Dry-AMD

Update

Healthcare

06.04.20

Pixium Vision — Prima 2 18-month data shows strong promise

Update

Healthcare

26.03.20

Pixium Vision — Strategy in place to mitigate COVID-19 effects

Flash note

Healthcare

05.03.20

Pixium Vision — Successful Prima activation in first US patient

Update

Healthcare

19.02.20

Pixium Vision — Wrapping up 2019 with a solid financial position

Update

Healthcare

27.01.20

Pixium Vision — US feasibility study now underway

research

Healthcare

07.11.19

Pixium Vision — Pixium to raise up to €10m to advance Prima

Flash note

Healthcare

07.11.19

Pixium Vision — Pixium to raise up to €10m to advance Prima

Update

Healthcare

28.10.19

Pixium Vision — Building feasibility data on way to pivotal study

Update

Healthcare

06.08.19

Pixium Vision — Refining Prima system before starting pivotal trial

Flash note

Healthcare

02.05.19

Pixium Vision — Pixium appoints new CEO

Outlook

Healthcare

12.04.19

Pixium Vision — Prima gearing up for a pivotal year

Update

Healthcare

19.02.19

Pixium Vision — Financials in line as Prima advances

research

Healthcare

19.02.19

Pixium Vision — Financials in line as Prima advances

Flash note

Healthcare

11.01.19

Pixium Vision — Positive interim six-month Prima data

Update

Healthcare

17.12.18

Pixium Vision — Encouraging signs in Prima EU feasibility study

research

Healthcare

08.08.18

Pixium Vision — H118 update reflects continued Prima progress

Outlook

Healthcare

08.03.18

Pixium Vision — Focus shifts to Prima as human trials proceed

Flash note

Healthcare

30.01.18

Pixium Vision — Successful Prima activation in first patient

Update

Healthcare

24.10.17

Pixium Vision — Pixium cleared to start EU Prima feasibility study

research

Healthcare

05.10.17

Pixium Vision — Pixium seeks to address short Iris II lifespan

Flash note

Healthcare

26.05.17

Pixium Vision — Forfait Innovation decision postponed

Outlook

Healthcare

30.03.17

Pixium Vision — Key advancements for Iris II and Prima in 2017

Flash note

Healthcare

12.01.17

Pixium Vision — Update 12 January 2017

Update

Healthcare

19.10.16

Pixium Vision — Update 19 October 2016

Update

Healthcare

27.07.16

Pixium Vision — Update 27 July 2016

Update

Healthcare

15.07.16

Pixium Vision — Update 15 July 2016

Update

Healthcare

25.02.16

Pixium Vision — Update 24 February 2016

Update

Healthcare

08.01.16

Pixium Vision — Update 7 January 2016

Initiation

Healthcare

22.09.15

Pixium Vision — Update 22 September 2015

Further insights

insight

Healthcare

06.03.19

Retinal implants

thematic

Healthcare

13.06.23

ASCO 2023 key takeaways

thematic

Healthcare

26.01.23

Machine learning in drug development

thematic

Healthcare

06.01.23

Outlook for 2023: Biotechs remain central to novel drug development

thematic

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

thematic

Healthcare

20.12.22

Cell and gene therapies

thematic

Healthcare

28.11.22

Drug delivery platforms

thematic

Healthcare

07.11.22

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

01.11.22

Neuroscience comeback

thematic

Consumer

05.10.22

IPO apocalypse

thematic

Healthcare

03.10.22

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

10.08.22

ESG, moving beyond the box tick

thematic

Healthcare

01.07.22

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

26.04.22

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

10.11.21

Artificial intelligence in drug discovery

thematic

Healthcare

27.07.21

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Healthcare

22.03.21

Seven things every investor should know about SIGA technologies & biological weapons

thematic

Healthcare

01.02.21

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Healthcare

30.10.19

Edison Exhibits- antibiotic development

thematic

Healthcare

17.07.19

The next wave in AMD

thematic

Healthcare

18.06.19

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

10.06.19

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

22.05.19

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

08.04.19

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Healthcare

04.03.19

Drug pricing – Market access and reimbursement

thematic

Healthcare

29.01.19

The diagnostics sector

thematic

Healthcare

21.06.17

ASCO 2017

thematic

Consumer

11.11.14

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

05.03.14

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Energy & Resources

04.03.14

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

01.03.13

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

07.12.12

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

30.08.12

Edison healthcare quarterly: Crisis? What crisis?

thematic

Healthcare

28.05.12

Equities

Equities by Sector

Sectors

Thematics

Latest

Healthcare-focused trusts: A sector on the mend

MediaWatch – One step forward, two steps back

ConsumerWatch – Don’t look down

Audiovisual

Latest

Recce Pharmaceuticals – executive interview

VEON – executive interview with CFO Joop Brakenhoff

VEON – executive interview with CEO Kaan Terzioğlu

About Edison

About Edison

Careers

Pixium Vision (PAR: PIX)

Latest Insights

Pixium Vision — Safeguard proceedings underway

Pixium Vision — Shareholder loan extends runway

Pixium Vision — Focusing on reaching the PRIMAvera milestone

Pixium Vision — Breakthrough designation provides validation

Sector

Balance Sheet

Share Price Performance

Financials

Research

Pixium Vision — Remote rehabilitation system approved

Pixium Vision — ESGO financing deal shores up balance sheet

Pixium Vision — First Prima implantation in Italy

Pixium Vision — Moving ahead as expected

Pixium Vision — PRIMAvera recruitment timing pushed out

Pixium Vision — Three-year data confirms continued Prima safety

Pixium Vision — Advancing towards sight restoration in dry-AMD

Pixium Vision – executive interview

Pixium Vision — Capital increase strengthens funding runway

Pixium Vision — Signalling an intent to access US investors

Pixium Vision — Back to basics as Second Sight deal is called off

Pixium Vision — Second Sight $28m financing adds clouds to deal

Pixium Vision — FY20 results in line, awaiting merger updates

Pixium Vision – Edison Open House interview

Pixium Vision — Pixium Vision to combine with Second Sight

Pixium Vision — ANSM approval to start PRIMAvera pivotal study

Pixium Vision — Q3 results in line, awaiting pivotal study approval

Pixium Vision — H120 results broadly in line

Pixium Vision — €7.3m capital increase completed

Pixium Vision — Restoring eyesight in advanced Dry-AMD

Pixium Vision — Prima 2 18-month data shows strong promise

Pixium Vision — Strategy in place to mitigate COVID-19 effects

Pixium Vision — Successful Prima activation in first US patient

Pixium Vision — Wrapping up 2019 with a solid financial position

Pixium Vision — US feasibility study now underway

Pixium Vision — Pixium to raise up to €10m to advance Prima

Pixium Vision — Pixium to raise up to €10m to advance Prima

Pixium Vision — Building feasibility data on way to pivotal study

Pixium Vision — Refining Prima system before starting pivotal trial

Pixium Vision — Pixium appoints new CEO

Pixium Vision — Prima gearing up for a pivotal year

Pixium Vision — Financials in line as Prima advances

Pixium Vision — Financials in line as Prima advances

Pixium Vision — Positive interim six-month Prima data

Pixium Vision — Encouraging signs in Prima EU feasibility study

Pixium Vision — H118 update reflects continued Prima progress

Pixium Vision — Focus shifts to Prima as human trials proceed

Pixium Vision — Successful Prima activation in first patient

Pixium Vision — Pixium cleared to start EU Prima feasibility study

Pixium Vision — Pixium seeks to address short Iris II lifespan

Pixium Vision — Forfait Innovation decision postponed

Pixium Vision — Key advancements for Iris II and Prima in 2017

Pixium Vision — Update 12 January 2017

Pixium Vision — Update 19 October 2016

Pixium Vision — Update 27 July 2016

Pixium Vision — Update 15 July 2016

Pixium Vision — Update 24 February 2016

Pixium Vision — Update 7 January 2016

Pixium Vision — Update 22 September 2015

Further insights

Retinal implants

ASCO 2023 key takeaways

Machine learning in drug development